Page last updated: 2024-08-24

plerixafor and Autoimmune Disease

plerixafor has been researched along with Autoimmune Disease in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Horuk, R; Pease, J1
Chen, H; Poznansky, MC; Tannous, BA; Wang, J1
Aboumrad, E; Madec, AM; Thivolet, C1
Billiau, A; Bridger, G; De Clercq, E; Hatse, S; Henson, GW; Matthys, P; Schols, D; Vermeire, K; Wuyts, A1

Reviews

1 review(s) available for plerixafor and Autoimmune Disease

ArticleYear
CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent.
    Pharmacological research, 2020, Volume: 159

    Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Benzylamines; Cyclams; Drug Contamination; HIV Infections; Humans; Neoplasms; Primary Immunodeficiency Diseases; Receptors, CXCR4; Signal Transduction; Tumor Microenvironment; Warts

2020

Other Studies

3 other study(ies) available for plerixafor and Autoimmune Disease

ArticleYear
Chemokine receptor antagonists.
    Journal of medicinal chemistry, 2012, Nov-26, Volume: 55, Issue:22

    Topics: Animals; Autoimmune Diseases; Humans; Receptors, Chemokine

2012
The CXCR4/CXCL12 (SDF-1) signalling pathway protects non-obese diabetic mouse from autoimmune diabetes.
    Clinical and experimental immunology, 2007, Volume: 148, Issue:3

    Topics: Adoptive Transfer; Animals; Autoimmune Diseases; Benzylamines; Cells, Cultured; Chemokine CXCL12; Chemokines, CXC; Cyclams; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; Heterocyclic Compounds; Islets of Langerhans; Lymph Nodes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Th2 Cells

2007
AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice.
    Journal of immunology (Baltimore, Md. : 1950), 2001, Oct-15, Volume: 167, Issue:8

    Topics: Animals; Arthritis, Experimental; Autoantigens; Autoimmune Diseases; Benzylamines; Chemokine CXCL12; Chemokines, CXC; Collagen Type II; Cyclams; Extremities; Heterocyclic Compounds; Hypersensitivity, Delayed; Interferon-gamma; Macrophage-1 Antigen; Mice; Mice, Inbred DBA; Mice, Knockout; Receptors, CXCR4

2001